Jonathan Krichev, MD
Family Medicine · Brownsboro, ALNPI 1407807621
Payments from drug & device makers
Across 707 payments — averaging $13.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Pfizer$883
- Lilly USA, LLC$739
- AstraZeneca$665
- GSK$651
- AbbVie$363
- plus $4K from 28 others
What the payments were for
- Food & beverage$9,198100%
- Education$330%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 262 | $2,205 |
| Pfizer | 60 | $883 |
| Lilly USA, LLC | 48 | $739 |
| AstraZeneca | 49 | $665 |
| GSK | 37 | $651 |
| AbbVie(2 entities) | 26 | $363 |
| Lundbeck LLC | 14 | $314 |
| Amgen | 18 | $310 |
| Merck | 18 | $310 |
| Bayer | 14 | $307 |
| Johnson & Johnson(2 entities) | 20 | $294 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 20 | $283 |
| Boehringer Ingelheim | 17 | $258 |
| Phathom Pharmaceuticals, Inc. | 26 | $249 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $201 |
| Amarin Pharma, Inc. | 10 | $181 |
| Biohaven Pharmaceutical Holding Company Ltd. | 11 | $166 |
| Abbott | 7 | $136 |
| Biohaven Pharmaceuticals, Inc. | 4 | $130 |
| Eisai Inc. | 9 | $129 |
| Kowa Pharmaceuticals America, Inc. | 5 | $79 |
| Teva Pharmaceuticals USA, Inc. | 4 | $68 |
| Idorsia Pharmaceuticals US Inc | 4 | $57 |
| Esperion Therapeutics, Inc. | 3 | $48 |
| Philips North America LLC | 2 | $31 |
| Zimmer Biomet | 1 | $28 |
| Sanofi Pasteur Inc. | 1 | $24 |
| Bioventus LLC | 1 | $23 |
| IBSA Pharma Inc. | 1 | $18 |
| Hologic Sales And Service, LLC | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Axsome Therapeutics, Inc. | 1 | $15 |
| Gilead | 1 | $14 |
How this compares
$9,231 in reported general payments places this provider in the 90th percentile of 1,680 family medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 115 | $156,523 |
| MounjaroTirzepatide | 87 | $119,716 |
| XareltoRivaroxaban | 72 | $73,192 |
| JardianceEmpagliflozin | 65 | $68,238 |
| FarxigaDapagliflozin Propanediol | 28 | $31,899 |
| EliquisApixaban | 29 | $31,659 |
| Repatha SureclickEvolocumab | 31 | $28,181 |
| Tresiba Flextouch U-200Insulin Degludec | 19 | $26,165 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $19,633 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 45 | $13,972 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $12,074 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 18 | $10,985 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 16 | $10,878 |
| BelsomraSuvorexant | 16 | $10,324 |
| Victoza 3-PakLiraglutide | 12 | $9,483 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $2,205 | $156,523115 claims |
| Lilly USA, LLCMounjaro | $739 | $119,71687 claims |
| Johnson & JohnsonXarelto | $294 | $73,19272 claims |
| Boehringer IngelheimJardiance | $258 | $68,23865 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $665 | $42,88446 claims |
| GSKTrelegy Ellipta, Arexvy, Shingrix | $651 | $38,96385 claims |
| PfizerEliquis, Paxlovid | $883 | $34,47950 claims |
| MerckBelsomra | $310 | $10,32416 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,680 family medicine providers in Alabama.
Other family medicine in Brownsboro
- Michael VaughnBirmingham$9.9M
- William NixonGuntersville$7.1M
- Randall QuinnCullman$5.4M
- Matthew CaldwellAthens$4.1M
- Michael CarterHuntsville$3.4M
- Howard RubensteinSaraland$3.3M
- Randle MiddletonHuntsville$3.3M
- Aaron KarrSheffield$3.1M
- Nidal MorrarFoley$3M
- Timothy HowardHuntsville$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.